Table 4.
Comparison of demographics and disease manifestations in MPO-ANCA-positive and PR3-ANCA-positive patients
|
MPO-ANCA |
PR3-ANCA |
P value | |
|---|---|---|---|
| (n = 125) | (n = 13) | ||
| Male/female |
47/78 |
6/7 |
0.56 |
| Mean (median) age (years) |
70.0 ± 1.04 (73) |
61.3 ± 3.2 (61) |
0.012 |
| Serum creatinine (mg/dl) |
1.94 ± 0.17 |
1.22 ± 0.53 |
0.19 |
| Interstitial lung disease |
57 (45.6) |
0 (0) |
0.0015 |
| Alveolar haemorrhage |
11 (8.8) |
1 (7.7) |
0.89 |
| Disease severity |
0.26 |
||
| Localised |
2 (1.6) |
1 (7.7) |
|
| Early systemic |
33 (26.4) |
2 (15.4) |
|
| Generalised |
68 (54.4) |
8 (61.5) |
|
| Severe |
22 (17.6) |
2 (15.4) |
|
| General performancea |
0.26 |
||
| 0/1/2/3/4 |
16/44/26/31/8 |
4/6/1/2/0 |
|
| BVASb | |||
| BVAS |
17.5 ± 0.71 |
17.5 ± 2.2 |
0.99 |
| General |
95 (76.0) |
10 (76.9) |
0.94 |
| Cutaneous |
30 (24.0) |
0 (0) |
0.046 |
| Mucous membranes/eyes |
16 (12.8) |
4 (30.8) |
0.08 |
| Ear, nose, and throat |
22 (17.6) |
12 (92.3) |
<0.0001 |
| Chest |
49 (39.2) |
7 (53.9) |
0.31 |
| Cardiovascular |
8 (6.4) |
2 (15.4) |
0.23 |
| Abdominal |
2 (1.6) |
0 (0) |
0.65 |
| Renal |
98 (78.4) |
6 (46.2) |
0.010 |
| Nervous system | 55 (44.0) | 4 (30.8) | 0.36 |
Values expressed as mean ± standard error or number (percentage) unless otherwise noted. Five patients who were double-positive for both ANCAs were excluded from this analysis. ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; MPO, myeloperoxidase; PR3, proteinase-3. aGeneral performance was categorised according to the World Health Organization performance status except category 5 (death). bDisease activity and patterns of organ involvement were defined by the BVAS 2003 scoring system.